Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Matthews, Hasan; Paldanius, Paivi; Proot, Pieter; Chiang, YannTong; Stumvoll, Michael; Del Prato, Stefano

doi:10.1016/s0140-6736(19)32131-2

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Copy For Citation

Matthews D. R. , Paldanius P. M. , Proot P., Chiang Y., Stumvoll M., Del Prato S.

LANCET, vol.394, no.10208, pp.1519-1529, 2019 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 394 Issue: 10208
Publication Date: 2019
Doi Number: 10.1016/s0140-6736(19)32131-2
Title of Journal : LANCET
Page Numbers: pp.1519-1529

Abstract

Background Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy has been suggested to offer more opportunities than a traditional stepwise approach, its validity remains to be determined.